University Clinic Ulm
Welcome,         Profile    Billing    Logout  
 13 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Buske, Christian
NCT01788020 / 2013-000506-37: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Completed
3
202
Europe
Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
University of Ulm, Centre Hospitalier de Lens (Co-Sponsor)
Waldenström's Macroglobulinemia
11/18
04/24
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
FORTplus, NCT05045664: Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

Recruiting
3
100
Europe
Standard, Experimental, Rituximab, Obinutuzumab
Heidelberg University
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
12/26
12/29
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Recruiting
2/3
210
Europe
Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA
University of Giessen
Hairy Cell Leukemia
12/25
12/27
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
ECWM-2, NCT03620903 / 2017-004362-95: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Active, not recruiting
2
53
Europe
Ibrutinib / Bortezomib / Rituximab, Imbruvica / Velcade / Mabthera
Christian Buske, University of Ulm, ClinAssess GmbH, Zentrum für Klinische Studien Ulm, Hoffmann-La Roche, Johnson & Johnson
Waldenstrom Macroglobulinemia
11/22
09/29
OLYMP-1, NCT03322865 / 2017-003149-56: Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting
2
56
Europe
Obinutuzumab, GA101
Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG
Marginal Zone Lymphoma
06/24
11/28
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Active, not recruiting
2
36
Europe
Copanlisib, Aliqopa, Rituximab, Truxima
Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer
Marginal Zone Lymphoma
06/24
12/29
VIWA-1, NCT05099471: Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Not yet recruiting
2
80
NA
Venetoclax; Rituximab, Venetoclax / Rituximab, DRC, Dexamethasone / Rituximab / Cyclophosphamide
University of Ulm, Ludwig-Maximilians - University of Munich, Zentrum für Klinische Studien Ulm, AbbVie, Pfizer, University Hospital Schleswig-Holstein, Campus Kiel
Waldenstrom Macroglobulinemia
01/28
12/32
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Recruiting
2
99
Europe
Carfilzomib + Ibrutinib, Ibrutinib
Christian Buske, Amgen, Janssen, LP
Waldenstrom Macroglobulinemia
02/28
02/28
NCT04268277: Pembrolizumab in MarginalzoneLymphoma a MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Terminated
N/A
22
Europe
Rituximab, Truxima, Pembrolizumab, Keytruda
University of Ulm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Merck Sharp & Dohme LLC, Celltrion Healthcare Co., LTD
Marginal Zone Lymphoma
12/24
12/24
Söling, Ulrike
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Recruiting
2/3
210
Europe
Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA
University of Giessen
Hairy Cell Leukemia
12/25
12/27
Wiegel, Thomas
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28

Download Options